Catalent Pharma Solutions has announced a commercial supply agreement with Palatin Technologies to globally launch Palatin’s bremelanotide pen injector product, which is used to treat female sexual dysfunction (FSD)
Bremelanotide, an on-demand, subcutaneous injectable peptide melanocortin receptor agonist, is designed to treat hypoactive sexual desire disorder, the most common form of FSD, in premenopausal women.
Phase 3 clinical trials are on-going, with a commercial launch anticipated in 2018.
“We are pleased that Palatin has chosen to partner with Catalent to commercialise this new and innovative treatment,” said Jonathan Arnold, Catalent’s vice president and general manager for advanced delivery technologies.
“Catalent provides flexible manufacturing solutions to meet our customers’ unique program requirements, and our expertise in sterile filling, device and delivery technologies, combined with our packaging capabilities, will facilitate bringing this important product to market faster.
“We selected Catalent as our partner because of their proven expertise in custom sterile manufacturing solutions, and their track record of successful new product introductions,” added Stephen Wills, chief financial officer and chief operating officer of Palatin.
“Catalent provides the infrastructure, technical expertise and flexibility to support commercialisation of this novel product.”
The bremelanotide pen devices will be produced at Catalent's 265,000 square foot Brussels, Belgium site, the company’s flagship sterile fill finish facility, with a syringe-filling capacity of over 100 million units.